New drug combo shows promise in shrinking breast tumors before surgery
NCT ID NCT05896566
First seen Nov 18, 2025 · Last updated May 13, 2026 · Updated 19 times
Summary
This study tested a new drug called giredestrant, alone or with triptorelin, against a standard treatment (anastrozole plus triptorelin) in 231 premenopausal women with early-stage, hormone-sensitive breast cancer. The goal was to see how well the drugs slow tumor growth before surgery. Results help doctors understand which treatments work best for this group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AOU maggiore della carita
Novara, Italy
-
ASL BR Azienda Sanitaria Locale
Brindisi, Italy
-
Azienda USL Toscana Centro
Prato, Italy
-
Brustzentrum Thurgau ( Spital AG)
Thurgau, Switzerland
-
CIOCC (Centro Integral Oncológico Clara Campal)
Madrid, Spain
-
Centre du Sein (Hopital Fribourgeois-Freiburger Spital)
Fribourg, Switzerland
-
Clinica Oncologica AOU Riuniti Ancona
Ancona, Italy
-
Gustave Roussy Cancer Center
Villejuif, France
-
H. la Fé
Valencia, Spain
-
HELIOS Klinikum Berlin Buch
Berlin, Germany
-
Helios Klinikum Wuppertal GmbH
Wuppertal, Germany
-
Hospital Universitari Son Espases
Palma de Mallorca, Spain
-
Humanitas Gavazzeni
Bergamo, Italy
-
IRCCS Ospedale Policlinico San Martino
Genova, Italy
-
Institut Catala D'oncologia ICO-Badalona
Badalona, Spain
-
Institut Catala d'Oncologia - Hospitalet
Barcelona, Spain
-
Istituti Clinici Scientifici Maugeri SpA-SB
Pavia, Italy
-
Istituto Europeo di Oncologia
Milan, Italy
-
Istituto oncologico romagnolo per lo studio dei tumori "Dino Amadori"
Meldola, Italy
-
KEM / Kliniken Essen Mitte
Essen, Germany
-
Kantonsspital Baden AG
Baden, Switzerland
-
Klinikum Südstadt
Rostock, Germany
-
Klinikum der J. W. Goethe Universität
Frankfurt, Germany
-
La Chaux-de-fonds, RH Neuchatelois (Hopital Les Cadolles)
La Chaux-de-Fonds, Switzerland
-
Onc Inst of Southern Switzerland (IOSI)
Bellinzona, Switzerland
-
Policlinico universitario Agostino Gemelli IRCCS Rome
Roma, Italy
-
Praxis Dr. Thorn, Praxis fur ambulante Tumortherapie (Praxis Thorn (Bethesda))
Basel, Switzerland
-
Praxisklinik Krebsheilkunde formerly MediOnko-Institut GbR
Berlin, Germany
-
Rimini Oncology department
Rimini, Italy
-
St. Anna Hirslanden
Lucerne, Switzerland
-
St. Elisabeth Krankenhaus
Leipzig, Germany
-
St. James Hospital
Dublin, Ireland
-
Universitiy Hospital Zurich
Zurich, Switzerland
-
University Hospital Galway
Galway, Ireland
-
Universitätsklinikum Mannheim GmbH
Mannheim, Germany
-
Universitätsklinikum Schleswig-Holstein
Kiel, Germany
-
Universitätsklinikum Ulm
Ulm, Germany
Conditions
Explore the condition pages connected to this study.